Business Wire

QC Laboratories, Inc. Awarded Nadcap Certification for Computed Radiography

19.7.2023 14:59:00 EEST | Business Wire | Press release

Share

QC Laboratories, Inc., a leading nondestructive testing and inspection services company, has announced that it has been awarded Nadcap certification for computed radiography (AC7114/10S) by the Performance Review Institute (PRI).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230717661945/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

The Nadcap certification is a highly respected accreditation that recognizes companies that demonstrate exceptional quality and performance in the aerospace industry. QC Laboratories, Inc. has met the rigorous requirements of the Nadcap audit for computed radiography, which includes stringent technical and quality standards, as well as an assessment of the company's personnel, facilities, and processes.

"We are thrilled to have achieved this certification, which reflects our unwavering commitment to providing the highest quality nondestructive testing and inspection services to our customers," said Jose Crespo, General Manager of QC Laboratories, Inc. "With the addition of Nadcap certification for Computed Radiography per ASTM E2033, combined with our powerful 450kV x-ray system, we are better equipped to serve our Nadcap subscriber customers in aerospace & defense, space, and beyond."

Computed radiography is a nondestructive testing method that uses digital imaging technology to produce high-quality images of internal structures and components. This technology enables the detection of defects and discontinuities in materials, such as cracks, porosity, and inclusions, without damaging them.

QC Laboratories, Inc. has had remarkable success in identifying defects in metal additive manufacturing parts using computed radiography. The company has been able to detect defects as small as 25 microns, which is crucial for ensuring the quality and reliability of complex metal parts made from exotic and refractory metals like those used in aircraft and rocket engine components, where high strength and thermodynamics are required.

With the new Nadcap certification for computed radiography (AC7114/10S), QC Laboratories, Inc. is now able to offer computed radiography services that meet the rigorous quality and technical standards of the aerospace industry. This certification further strengthens the company's position as a trusted provider of nondestructive testing and inspection services to customers in a wide range of industries.

About QC Laboratories, Inc.

QC Laboratories, Inc. is a nondestructive testing laboratory in Hollywood, Florida, USA. The company was founded in 1965 and offers various testing services, including nondestructive testing (NDT), chemical processing, and consulting services.

QC Laboratories serves a variety of industries, including aerospace, additive manufacturing, automotive, defense, manufacturing, and consumer products. The laboratory is accredited by the American Society for Nondestructive Testing (ASNT) and is certified by the Federal Aviation Administration (FAA) and Nadcap (Performance Review Institute) for NDT services.

QC Laboratories has a team of experienced nondestructive engineers and technicians using advanced testing equipment and techniques to provide accurate and reliable results. The laboratory is committed to delivering high-quality services and maintaining the highest standards of professionalism and ethics.

For more information about QC Laboratories' new capability for pre-penetrant etching of metal AM parts, please visit www.qclabs.net or contact the laboratory directly.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Althea Lawson
QC Laboratories, Inc.
Phone: (954) 925-0499
Email: info@qclabs.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye